Functional contributions of carbohydrate on AIDS virus glycoprotein.

Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. J Biol Chem (2012) 1.42

Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategy. Proc Natl Acad Sci U S A (2011) 1.40

Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J Virol (2013) 1.15

Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. PLoS One (2014) 0.84

Single genome analysis reveals genetic characteristics of Neuroadaptation across HIV-1 envelope. Retrovirology (2014) 0.84

Amino Acid Substitutions Improve the Immunogenicity of H7N7HA Protein and Protect Mice against Lethal H7N7 Viral Challenge. PLoS One (2015) 0.77

Phenotypic and Functional Characterization of Monoclonal Antibodies with Specificity for Rhesus Macaque CD200, CD200R and Mincle. PLoS One (2015) 0.75

Antibody neutralization and escape by HIV-1. Nature (2003) 21.48

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell (2000) 14.43

Mechanism of protein translocation across the endoplasmic reticulum membrane. Annu Rev Cell Biol (1986) 5.28

A role for carbohydrates in immune evasion in AIDS. Nat Med (1998) 5.06

Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol (2002) 4.63

The role of polyprenol-linked sugars in glycoprotein synthesis. Annu Rev Biochem (1976) 4.62

Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1990) 4.46

Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature (1992) 4.16

Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J Virol (1991) 3.62

The synthesis of complex-type oligosaccharides. II. Characterization of the processing intermediates in the synthesis of the complex oligosaccharide units of the vesicular stomatitis virus G protein. J Biol Chem (1978) 3.43

Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother (1997) 2.98

DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus. J Virol (2001) 2.95

Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol (1997) 2.88

Processing of high mannose oligosaccharides to form complex type oligosaccharides on the newly synthesized polypeptides of the vesicular stomatitis virus G protein and the IgG heavy chain. J Biol Chem (1978) 2.83

Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature (1987) 2.72

Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J Virol (1993) 2.65

Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol (2004) 2.62

Studies on the attachment of carbohydrate to ovalbumin nascent chains in hen oviduct. J Biol Chem (1976) 2.55

V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J Virol (2000) 2.45

Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. Proc Natl Acad Sci U S A (1987) 2.25

The synthesis of complex-type oligosaccharides. III. Identification of an alpha-D-mannosidase activity involved in a late stage of processing of complex-type oligosaccharides. J Biol Chem (1978) 2.16

Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol (2007) 2.05

Changes in the extracellular envelope glycoprotein of variants that evolve during the course of simian immunodeficiency virus SIVMne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition. J Virol (1998) 1.98

Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses (2003) 1.92

HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol (2010) 1.90

The amino acid at the X position of an Asn-X-Ser sequon is an important determinant of N-linked core-glycosylation efficiency. J Biol Chem (1996) 1.90

HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog (2007) 1.90

Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. J Virol (1993) 1.88

Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses (2006) 1.83

Immediate glycosylation of Sindbis virus membrane proteins. Cell (1977) 1.82

Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol (2003) 1.80

The biosynthesis of mannose-containing glycoproteins: a possible lipid intermediate. Biochem Biophys Res Commun (1969) 1.77

Rhesus macaque dendritic cells efficiently transmit primate lentiviruses independently of DC-SIGN. Proc Natl Acad Sci U S A (2002) 1.59

Recent insights into the biological roles of mucin-type O-glycosylation. Glycoconj J (2008) 1.53

The structures of the galactose-containing sugar chains of ovalbumin. J Biol Chem (1978) 1.47

Mucin-type O-glycosylation--putting the pieces together. FEBS J (2009) 1.46

Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Virology (1996) 1.45

Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120. AIDS Res Hum Retroviruses (1998) 1.40

Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein. J Virol (1998) 1.39

Antigenic variation of SIV: mutations in V4 alter the neutralization profile. Virology (1996) 1.35

Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. J Virol (2004) 1.31

Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J Gen Virol (2000) 1.30

Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. J Virol (2008) 1.30

Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain. J Virol (2001) 1.29

Legitimate and illegitimate cleavage of human immunodeficiency virus glycoproteins by furin. J Virol (1993) 1.29

Initial glycosylation of proteins with acetylgalactosaminylserine linkages. Proc Natl Acad Sci U S A (1979) 1.27

Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. Int J Biochem Cell Biol (2008) 1.23

Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol (2006) 1.21

HIV-1 assembly in macrophages. Retrovirology (2010) 1.20

Role of N-linked glycans in the interaction between the envelope glycoprotein of human immunodeficiency virus and its CD4 cellular receptor. Structural enzymatic analysis. J Exp Med (1989) 1.20

Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. J Virol (1996) 1.17

Resistance of native, oligomeric envelope on simian immunodeficiency virus to digestion by glycosidases. J Virol (2000) 1.16

Relationships between plasma membrane microdomains and HIV-1 assembly. Biol Cell (2010) 1.16

Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis. Mol Pharmacol (2005) 1.10

Infectivities of human and other primate lentiviruses are activated by desialylation of the virion surface. J Virol (1996) 1.08

Castanospermine and other plant alkaloid inhibitors of glucosidase activity block the growth of HIV. Lancet (1987) 1.06

Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120. J Virol (2007) 1.05

Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile. J Biol Chem (2010) 1.04

Review: Soluble innate immune pattern-recognition proteins for clearing dying cells and cellular components: implications on exacerbating or resolving inflammation. Innate Immun (2010) 1.04

Mannose binding lectin (MBL) and HIV. Mol Immunol (2005) 1.02

Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4. J Virol (2005) 0.99

The evolutionary history of the CD209 (DC-SIGN) family in humans and non-human primates. Genes Immun (2008) 0.97

Study of the interaction of HIV-1 and HIV-2 envelope glycoproteins with the CD4 receptor and role of N-glycans. AIDS Res Hum Retroviruses (1992) 0.96

Capture and transfer of simian immunodeficiency virus by macaque dendritic cells is enhanced by DC-SIGN. J Virol (2002) 0.94

Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo. J Virol (2008) 0.94

The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp160. J Gen Virol (1995) 0.93

Inhibition of DC-SIGN-mediated trans infection of T cells by mannose-binding lectin. Immunology (2003) 0.92

Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120. Vaccine (2005) 0.91

Simian immunodeficiency virus from the sooty mangabey and rhesus macaque is modified with O-linked carbohydrate. J Virol (2010) 0.90

Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies. J Virol (2008) 0.89

Glycosyltransferase and sulfotransferase gene expression profiles in human monocytes, dendritic cells and macrophages. Glycoconj J (2009) 0.88

DC-SIGN from African green monkeys is expressed in lymph nodes and mediates infection in trans of simian immunodeficiency virus SIVagm. J Virol (2004) 0.88

Interaction of human immunodeficiency virus (HIV) glycans with lectins of the human immune system. Curr Protein Pept Sci (2006) 0.81

N-linked oligosaccharides of simian immunodeficiency virus envelope glycoproteins are dispensable for the interaction with the CD4 receptor. Biochem Biophys Res Commun (1993) 0.79

Fundamental difference in the content of high-mannose carbohydrate in the HIV-1 and HIV-2 lineages. J Virol (2010) 0.79

Biosynthesis of blood group active glycoproteins: a peptidyl: alpha-N-acetylgalactosaminyltransferase from human submaxillary gland and stomach mucosal tissue. Biochem Biophys Res Commun (1970) 0.78

HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48

Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med (2004) 6.33

Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31

Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog (2006) 4.80

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med (2009) 3.25

HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol (2006) 2.72

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol (2002) 2.63

Viral persistence: HIV's strategies of immune system evasion. Annu Rev Med (2002) 2.51

Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol (2006) 2.33

Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol (2005) 2.01

A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J Virol (2002) 1.97

Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol (2003) 1.80

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology (2006) 1.67

Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol (2002) 1.67

CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol (2002) 1.66

ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog (2012) 1.60

Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J Virol (2003) 1.60

Induction of a virus-specific effector-memory CD4+ T cell response by attenuated SIV infection. J Exp Med (2006) 1.55

Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol (2004) 1.44

Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J Virol (2002) 1.44

Cell tropism of simian immunodeficiency virus in culture is not predictive of in vivo tropism or pathogenesis. Am J Pathol (2004) 1.43

Cloning and analysis of microRNAs encoded by the primate gamma-herpesvirus rhesus monkey rhadinovirus. Virology (2007) 1.40

MHC heterozygote advantage in simian immunodeficiency virus-infected Mauritian cynomolgus macaques. Sci Transl Med (2010) 1.38

Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. J Virol (2004) 1.31

Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys. J Virol (2003) 1.28

Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J Virol (2008) 1.27

Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus. J Virol (2003) 1.24

Direct relationship between suppression of virus-specific immunity and emergence of cytomegalovirus disease in simian AIDS. J Virol (2003) 1.19

Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239. J Virol (2005) 1.17

Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J Virol (2013) 1.16

Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus. J Virol (2005) 1.13

A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase. J Virol (2002) 1.12

A genetic system for rhesus monkey rhadinovirus: use of recombinant virus to quantitate antibody-mediated neutralization. J Virol (2006) 1.12

Retroviral recombination in vivo: viral replication patterns and genetic structure of simian immunodeficiency virus (SIV) populations in rhesus macaques after simultaneous or sequential intravaginal inoculation with SIVmac239Deltavpx/Deltavpr and SIVmac239Deltanef. J Virol (2005) 1.10

Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response. J Virol (2008) 1.09

The tale of the long tail: the cytoplasmic domain of HIV-1 gp41. J Virol (2012) 1.09

Small nuclear RNAs encoded by Herpesvirus saimiri upregulate the expression of genes linked to T cell activation in virally transformed T cells. Curr Biol (2005) 1.07

The cytoplasmic domain of the HIV-1 glycoprotein gp41 induces NF-κB activation through TGF-β-activated kinase 1. Cell Host Microbe (2012) 1.06

Envelope glycoprotein cytoplasmic domains from diverse lentiviruses interact with the prenylated Rab acceptor. J Virol (2002) 1.05

A novel approach for producing lentiviruses that are limited to a single cycle of infection. J Virol (2004) 1.03

Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology (2006) 1.02

Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4. J Virol (2005) 0.99

Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo. J Virol (2008) 0.94

Vaccine protection against simian immunodeficiency virus in monkeys using recombinant gamma-2 herpesvirus. J Virol (2011) 0.91

Diversity of envelope genes from an uncloned stock of SIVmac251. AIDS Res Hum Retroviruses (2010) 0.91

Simian immunodeficiency virus from the sooty mangabey and rhesus macaque is modified with O-linked carbohydrate. J Virol (2010) 0.90

Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein. J Virol (2011) 0.87

An AIDS vaccine: no time to give up. Lancet (2004) 0.86

Glycoprotein gene sequence variation in rhesus monkey rhadinovirus. Virology (2010) 0.86

Modulation of HIV and SIV neutralization sensitivity by DC-SIGN and mannose-binding lectin. Virology (2007) 0.85

Extreme dependence of gH and gL expression on ORF57 and association with highly unusual codon usage in rhesus monkey rhadinovirus. J Virol (2008) 0.83

p6gag of human and simian immunodeficiency viruses is tolerant to small in-frame deletions downstream of the late domain. Virology (2005) 0.83

Infection and persistence of rhesus monkey rhadinovirus in immortalized B-cell lines. J Virol (2006) 0.81

Infectivity and neutralization of simian immunodeficiency virus with FLAG epitope insertion in gp120 variable loops. J Virol (2007) 0.81

Rhesus monkey rhadinovirus uses eph family receptors for entry into B cells and endothelial cells but not fibroblasts. PLoS Pathog (2013) 0.81

Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus. J Virol (2012) 0.81

Rhesus monkey rhadinovirus ORF57 induces gH and gL glycoprotein expression through posttranscriptional accumulation of target mRNAs. J Virol (2011) 0.81

Fundamental difference in the content of high-mannose carbohydrate in the HIV-1 and HIV-2 lineages. J Virol (2010) 0.79

PRA1 co-localizes with envelope but does not influence primate lentivirus production, infectivity or envelope incorporation. J Gen Virol (2005) 0.76

Localization of productively infected cells in the spleen and Peyer's patches of rhesus macaques during acute infection with SIVmac239Δnef-enhanced green fluorescent protein. AIDS Res Hum Retroviruses (2014) 0.75

A plea for justice for jailed medical workers. Science (2006) 0.75